title: Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists.
abstract: In the present study we assessed the effects of ipriflavone in the prevention of increased bone turnover and the rapid bone loss that follows medical induced hypogonadism caused by the administration of a gonadotropin hormone-releasing hormone agonist (GnRH-A). In a double blind, placebo-controlled study, ipriflavone (600 mg/day, tdd (three divided doses)) or identical placebo tablets were given with 500 mg/day of calcium to patients treated with 3.75 mg leuproreline acetate every 30 days, for 6 months. In placebo-treated subjects (n = 39), urinary hydroxyproline excretion and plasma bone GLA protein levels showed a substantial (P < 0.01) increase, while spine bone density and total body bone density significantly (P < 0.01) decreased after 3 and 6 months of GnRH-A administration. Conversely, in ipriflavone treated group (n = 39), no significant difference in bone markers and bone density was evidenced. These data indicate that ipriflavone can restrain the bone remodeling processes and prevent the rapid bone loss that follows medical induced hypogonadism. Thus, ipriflavone administration can be of value in the prevention of osteopenia in women treated with GnRH-A.
authors.affiliation: Department of Obstetrics and Gynecology University of Pisa, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Gambacciani
authors.forename: A
authors.initials: A
authors.lastname: Spinetti
authors.forename: L
authors.initials: L
authors.lastname: Piaggesi
authors.forename: B
authors.initials: B
authors.lastname: Cappagli
authors.forename: F
authors.initials: F
authors.lastname: Taponeco
authors.forename: P
authors.initials: P
authors.lastname: Manetti
authors.forename: C
authors.initials: C
authors.lastname: Weiss
authors.forename: G C
authors.initials: GC
authors.lastname: Teti
authors.forename: P
authors.initials: P
authors.lastname: La Commare
authors.forename: V
authors.initials: V
authors.lastname: Facchini
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D001851:Bone Diseases, Metabolic / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000502:physiology; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007529:Isoflavones / Q000627:therapeutic use*; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D017697:Premenopause / Q000378:metabolism* / Q000502:physiology; D013997:Time Factors
chemical_list: D007529:Isoflavones; D015675:Osteocalcin; D007987:Gonadotropin-Releasing Hormone; C018986:ipriflavone; D006909:Hydroxyproline